In a further approach, the publicly available Pan-Cancer Atlas (n = 10,967 cases including approximately 600 CRC cases) and The Cancer Genome Atlas (TCGA; n = 640 CRC cases) databases were screened for genomic amplifications/gains (amp/gain) in either ATF6 alone (ATF6-only), FASN alone (FASN-only) or in both genes simultaneously (ATF6 + FASN). This evidence concerns the gene ATF6 and colorectal carcinoma.